Genenta Science (GNTA) Competitors $3.82 +0.00 (+0.13%) As of 07/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. AVTE, DBVT, ALLO, ZYBT, ACB, SCPH, INZY, VOR, ANNX, and AARDShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Aerovate Therapeutics (AVTE), DBV Technologies (DBVT), Allogene Therapeutics (ALLO), Zhengye Biotechnology (ZYBT), Aurora Cannabis (ACB), scPharmaceuticals (SCPH), Inozyme Pharma (INZY), Vor Biopharma (VOR), Annexon (ANNX), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Its Competitors Aerovate Therapeutics DBV Technologies Allogene Therapeutics Zhengye Biotechnology Aurora Cannabis scPharmaceuticals Inozyme Pharma Vor Biopharma Annexon Aardvark Therapeutics Genenta Science (NASDAQ:GNTA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Do institutionals and insiders believe in GNTA or AVTE? 15.1% of Genenta Science shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher earnings and valuation, GNTA or AVTE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$9.64MN/AN/AAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.90 Does the media favor GNTA or AVTE? In the previous week, Genenta Science had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Genenta Science and 0 mentions for Aerovate Therapeutics. Genenta Science's average media sentiment score of 1.89 beat Aerovate Therapeutics' score of 0.00 indicating that Genenta Science is being referred to more favorably in the media. Company Overall Sentiment Genenta Science Very Positive Aerovate Therapeutics Neutral Which has more risk and volatility, GNTA or AVTE? Genenta Science has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Is GNTA or AVTE more profitable? Genenta Science's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A Aerovate Therapeutics N/A -90.19%-77.47% Do analysts prefer GNTA or AVTE? Genenta Science currently has a consensus target price of $25.00, suggesting a potential upside of 556.34%. Given Genenta Science's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genenta Science is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryGenenta Science beats Aerovate Therapeutics on 10 of the 11 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.68M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E RatioN/A21.1828.1020.05Price / SalesN/A286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book5.158.378.665.87Net Income-$9.64M-$55.19M$3.25B$258.55M7 Day Performance1.03%5.88%4.22%3.73%1 Month Performance25.05%17.33%10.51%11.75%1 Year Performance-9.09%4.42%34.40%18.03% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.7341 of 5 stars$3.810.0%$25.00+556.3%-9.5%$69.68MN/A0.007AVTEAerovate TherapeuticsN/A$9.47-0.4%N/A-87.6%$274.49MN/A-3.1720High Trading VolumeDBVTDBV Technologies3.9053 of 5 stars$9.50-5.0%$14.75+55.3%+85.8%$273.90MN/A-1.9380Upcoming EarningsGap UpALLOAllogene Therapeutics3.2649 of 5 stars$1.32+5.6%$8.44+539.7%-48.5%$273.41M$20K-1.07310Positive NewsZYBTZhengye BiotechnologyN/A$5.69flatN/AN/A$268.38M$25.53M0.00278Positive NewsGap UpACBAurora Cannabis0.2807 of 5 stars$4.70+3.8%N/A-16.4%$264.36M$343.29M42.731,130SCPHscPharmaceuticals4.3806 of 5 stars$5.13+3.8%$14.00+172.9%+12.4%$260.79M$41.98M-2.6930News CoverageINZYInozyme Pharma2.7939 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750VORVor Biopharma3.8809 of 5 stars$2.05-7.2%$5.63+174.6%+131.2%$256.17MN/A-1.24140ANNXAnnexon2.4431 of 5 stars$2.47+6.5%$12.50+406.1%-59.4%$254.54MN/A-2.0960AARDAardvark TherapeuticsN/A$12.00+3.3%$33.00+175.0%N/A$252.11MN/A0.0018 Related Companies and Tools Related Companies Aerovate Therapeutics Competitors DBV Technologies Competitors Allogene Therapeutics Competitors Zhengye Biotechnology Competitors Aurora Cannabis Competitors scPharmaceuticals Competitors Inozyme Pharma Competitors Vor Biopharma Competitors Annexon Competitors Aardvark Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
